Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.6 USD | -0.73% | +3.63% | -17.20% |
04-01 | Dynavax Technologies Corporation Announces Chief Financial Officer Changes | CI |
02-23 | Dynavax Technologies Reports Breakeven Q4 Earnings, Lower Revenue | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's profit outlook over the next few years is a strong asset.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 50.78 times its estimated earnings per share for the ongoing year.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.31% | 1.53B | B- | ||
-1.07% | 104B | B+ | ||
+7.07% | 97.47B | B+ | ||
+5.71% | 22.25B | B | ||
-12.90% | 21.68B | B+ | ||
-9.70% | 18.2B | A- | ||
-39.98% | 17.02B | A- | ||
-10.30% | 16.36B | B | ||
+8.39% | 14.39B | C+ | ||
+39.69% | 12.37B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DVAX Stock
- Ratings Dynavax Technologies Corporation